Advancements in biosensing technology showcased at CES suggest a shift in wearables, offering more actionable health data. Biosensors, wearable devices adhered to the body, go beyond traditional wearables by providing extensive health insights. Abbott's Lingo, a biosensor for continuous glucose monitoring (CGM), targets not only those with diabetes but also a wider audience. Lingo, already launched in the UK, is set to roll out in the US this year, offering data on blood sugar and, eventually, ketones. Priced at 89 euros for a two-week pack, it aims to inform users about the impact of diet on blood sugar and daily trends. While other glucose-monitoring companies exist, Lingo's non-prescription accessibility may democratize valuable health information, potentially benefiting individuals in a pre-diabetic state. Biosensors represent a promising evolution in wearables, bridging the gap between health-conscious consumers and comprehensive health data.